Actinium Pharmaceuticals Has a Long Collaborative History with Sloan Kettering
SANTA MONICA, CA / ACCESSWIRE / February 28, 2017 / Online Media Group Inc. covers Actinium Pharmaceuticals (NYSE MKT: ATNM).
The strong collaboration between Actinium Pharmaceuticals and the prestigious Memorial Sloan Kettering Cancer Center (MSK) was on full display during a recent presentation at a satellite symposium to the 2017 BMT Tandem Meetings (http://www.onclive.com/conference-coverage/bmt-tandem-2017/novel-pretransplant-conditioning-regimens-seek-to-reduce-relapse-in-blood-cancers).
In a talk focused on novel therapeutic strategies to prevent relapse, the most important cause of treatment failure after hematopoietic stem cell transplant (HSCT) in patients with hematologic malignancies, Sergio Giralt, MD, Chief of the Adult Bone Marrow Transplantation at Sloan Kettering, highlighted Actinium Pharmaceuticals' Iomab-B.
The renowned physician was optimistic about the potential of adding targeted agents to the pretransplant conditioning regimen to increase the antitumor effect. Of these options, Dr. Giralt focused extensively on Actinium's lead product candidate, Iomab-B, a radiolabeled antibody-drug conjugate targeted against CD45; and rituximab, an antibody directed against CD20.
Actinium's Iomab-B is a therapy designed to help prepare patients for a hematopoietic stem cell transplant. Actinium is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML), age 55 and older.
Internationally recognized, Dr. Giralt is board certified in internal medicine with subspecialties in medical oncology and hematology. He is an active member of the American Medical Association, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation (ASBMT), International Society of Hematotherapy and Graft Engineering, International Society of Haematology, and the Gerontological Society of America.
Actinium, a company founded on technology developed by MSK, continues to work closely with the world-renowned cancer center, a relationship that has only been enhanced since the company in-licensed Iomab-B. Sergio Giralt, MD, along with other leading physicians at Sloan Kettering, currently serves on the Advisory Board of Actinium Pharmaceuticals.
For more information on Iomab-B and the other therapeutic candidates in Actinium's robust product pipeline visit: http://www.actiniumpharma.com/
Legal Disclaimer:
Online Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Online Media Group, Inc. may have received compensation from the companies mentioned in this release.
For further information:
Online Media Group, Inc.
310.413.5788
SOURCE: Online Media Group Inc.